CNS Pharmaceuticals, Inc.(CNSP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CNSP CNS Pharmaceuticals, Inc.

Market Closed 12-05 16:00:00 EST

6.60

+0.09

+1.38%

盘后6.60

+0.000.00%

19:09 EST

High6.94	Low6.54	Vol8.61K
Open6.68	D1 Closing6.51	Amplitude6.12%
Mkt Cap4.09M	Tradable Cap3.56M	Total Shares620.30K
T/O57.39K	T/O Rate1.60%	Tradable Shares539.50K
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CNSP","market":"US","secType":"STK","nameCN":"CNS Pharmaceuticals, Inc.","latestPrice":6.6,"timestamp":1764968400000,"preClose":6.51,"halted":0,"volume":8606,"hourTrading":{"tag":"盘后","latestPrice":6.6,"preClose":6.6,"latestTime":"19:09 EST","volume":213,"amount":1426.53,"timestamp":1764979778142},"delay":0,"floatShares":539500,"shares":620300,"eps":-85.406334,"marketStatus":"Market Closed","change":0.09,"latestTime":"12-05 16:00:00 EST","open":6.68,"high":6.9387,"low":6.54,"amount":57392.3356682,"amplitude":0.061244,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-85.406334,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765184400000},"marketStatusCode":7,"adr":0,"listingDate":1573189200000,"exchange":"NASDAQ","adjPreClose":6.51,"postHourTrading":{"tag":"盘后","latestPrice":6.6,"preClose":6.6,"latestTime":"19:09 EST","volume":213,"amount":1426.53,"timestamp":1764979778142},"volumeRatio":1.6362460836993753},"requestUrl":"/m/hq/s/CNSP/wiki","defaultTab":"wiki","newsList":[{"id":"2585743129","title":"CNS Pharmaceuticals Held Annual Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2585743129","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585743129?lang=en_us&edition=fundamental","pubTime":"2025-11-22 06:19","pubTimestamp":1763763597,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals Inc. held its Annual Meeting of Stockholders on November 17, 2025. Shareholders approved amendments to the company's 2020 Equity Plan, increasing the number of shares authorized for issuance under the plan. The meeting also saw the election of John Climaco, Jerzy  Gumulka, Jeffry R. Keyes, Faith Charles, Bettina Cockroft, and Amy Mahery to the board of directors. In addition, shareholders approved amendments to the company's Articles of Incorporation to increase the total number of authorized shares of common stock from 25,000,000 to 300,000,000 and the total number of authorized shares of preferred stock from 416,667 to 5,000,000.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CNS Pharmaceuticals Inc. published the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nNDL9lKggK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNSP","BK4007"],"gpt_icon":0},{"id":"2584264036","title":"CNS Pharmaceuticals reports Q3 net loss of $3.3 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2584264036","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584264036?lang=en_us&edition=fundamental","pubTime":"2025-11-17 21:35","pubTimestamp":1763386522,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals Inc. reported a net loss of approximately $3.3 million for the three months ended September 30, 2025, compared to a net loss of $5.6 million for the same period in 2024. Research and development expenses were $2.2 million, down from $4.2 million in the prior year period. General and administrative expenses were $1.1 million, compared to $1.4 million in the third quarter of 2024. The company stated its cash is expected to fund operations into the second half of 2026. During the period, CNS Pharmaceuticals focused on advancing its lead program, TPI 287, for glioblastoma multiforme, progressing toward a Phase 2 study and planning to engage with the FDA on study design in early 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or leg","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDLZz49K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNSP","BK4007"],"gpt_icon":0},{"id":"2582874161","title":"CNS Pharmaceuticals Unveils New Glioblastoma and Pediatric DMG Clinical Trial Results at SNO 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2582874161","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582874161?lang=en_us&edition=fundamental","pubTime":"2025-11-10 21:45","pubTimestamp":1762782325,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals Inc. has announced the acceptance of three abstracts for poster presentation at the 2025 Society of Neuro-Oncology  Annual Meeting, scheduled for November 19-23, 2025, in Honolulu, Hawaii. The presentations will cover preliminary data on the activity of Berubicin against pediatric diffuse midline glioma  cells, the evaluation of TPI 287 in combination with Bevacizumab in glioblastoma  and other central nervous system diseases, and the primary results of a randomized clinical trial comparing Berubicin versus Lomustine in patients with glioblastoma after failure of primary therapy. The results of these studies will be presented at the SNO meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CNS Pharmaceuticals Inc.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDLXD0Cq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNSP","BK4007"],"gpt_icon":0},{"id":"2574189107","title":"CNS Pharmaceuticals Inc announces date for annual stockholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2574189107","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574189107?lang=en_us&edition=fundamental","pubTime":"2025-10-11 04:31","pubTimestamp":1760128301,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals Inc. has announced that its Annual Meeting of Stockholders will be held virtually on November 17, 2025. During the meeting, stockholders will vote on the election of six nominees to the Board of Directors, each to serve until the 2026 annual meeting of stockholders or until their successors are qualified and elected.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CNS Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 10, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251010:nNDL37Z9cC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CNSP"],"gpt_icon":0},{"id":"2566131977","title":"CNS Pharmaceuticals Raised to Buy From Hold by Maxim Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2566131977","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566131977?lang=en_us&edition=fundamental","pubTime":"2025-09-12 22:18","pubTimestamp":1757686680,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CNSP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 12, 2025 10:18 ET (14:18 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNSP","CNS"],"gpt_icon":0},{"id":"2566186971","title":"CNS Pharmaceuticals Inc : Maxim Group  Raises to Buy From Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2566186971","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566186971?lang=en_us&edition=fundamental","pubTime":"2025-09-12 20:40","pubTimestamp":1757680808,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250912:nFWN3UZ0OK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CNSP","BK4007"],"gpt_icon":0},{"id":"2561462497","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2561462497","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561462497?lang=en_us&edition=fundamental","pubTime":"2025-08-21 19:52","pubTimestamp":1755777131,"startTime":"0","endTime":"0","summary":"ModivCare  shares were 48% lower pre-bell Thursday, a day after the company said it filed for Chapter 11 protection in a Texas court.Coty  stock was down 19% after the company reported late Wednesday a wider fiscal Q4 adjusted loss amid lower revenue.Mega Fortune  shares were 17% lower following a 5.2% loss in the previous session.CNS Pharmaceuticals  stock was down 14%, paring Wednesday's rally.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00B19Z3B42.SGD","BK4116","COTY","IE0002270589.USD","MODV","IE00B19Z3581.USD","CNSP","BK4196","IE00B7SZLL34.SGD","MGRT","BK4183","BK4007","IE00BFMHRM44.USD"],"gpt_icon":0},{"id":"2559911581","title":"CNS Pharmaceuticals Reports Q2 2025 Results: Net Loss Narrows to $2.4M, R&D Expenses Rise Slightly","url":"https://stock-news.laohu8.com/highlight/detail?id=2559911581","media":"Reuters","labels":["dataReport","event","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559911581?lang=en_us&edition=fundamental","pubTime":"2025-08-15 20:05","pubTimestamp":1755259516,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CNS Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire  on August 15, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250815:nNDL1Vrh8T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,event,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CNSP"],"gpt_icon":0},{"id":"2559967503","title":"CNS Pharmaceuticals Q2 EPS $(6.42) Beats $(9.60) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2559967503","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559967503?lang=en_us&edition=fundamental","pubTime":"2025-08-15 05:47","pubTimestamp":1755208022,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals (NASDAQ:CNSP) reported quarterly losses of $(6.42) per share which beat the analyst consensus estimate of $(9.60) by 33.13 percent. This is a 98.09 percent increase over losses of $(336.00) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/47142953/cns-pharmaceuticals-q2-eps-6-42-beats-9-60-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNSP","CNS"],"gpt_icon":0},{"id":"2559895700","title":"CNS Pharmaceuticals Inc. to Present at Webull Financial Corporate Connect Webinar Series: Biotech/MedTech","url":"https://stock-news.laohu8.com/highlight/detail?id=2559895700","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559895700?lang=en_us&edition=fundamental","pubTime":"2025-08-14 21:15","pubTimestamp":1755177351,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals Inc. , a biopharmaceutical company focused on developing novel treatments for brain and central nervous system cancers, will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech. The virtual event is scheduled for August 19-21, 2025, with CNS Pharmaceuticals' presentation taking place on Tuesday, August 19, at 2:40 PM ET.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CNS Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire  on August 14, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250814:nNDL3Yqln7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4127","CNSP","BULL"],"gpt_icon":0},{"id":"2558557014","title":"CNS Pharmaceuticals Inc  expected to post a loss of $9.60 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2558557014","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558557014?lang=en_us&edition=fundamental","pubTime":"2025-08-09 07:28","pubTimestamp":1754695685,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals Inc  expected to post a loss of $9.60 a share - Earnings Preview CNS Pharmaceuticals Inc CNSP.OQ CNSP.O is expected to  report resultson August 12 (estimated) for the period ending","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250808:nL8N3U03Y4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNSP"],"gpt_icon":0},{"id":"2553265402","title":"CNS Pharmaceuticals Announces 1-for-12 Reverse Stock Split Effective July 22, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2553265402","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553265402?lang=en_us&edition=fundamental","pubTime":"2025-07-23 04:40","pubTimestamp":1753216836,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals Inc. announced a 1-for-12 reverse stock split of its common stock, effective July 22, 2025. The company's shares will continue trading on the Nasdaq Capital Market under the symbol \"CNSP\" with a new CUSIP number 18978H508. The reverse split will consolidate every 12 shares into one, affecting all shareholders uniformly and reducing the authorized shares to 25 million. No fractional shares will be issued; instead, cash payments will be made for fractional entitlements. The par value remains unchanged at $0.001 per share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CNS Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retriev","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250722:nNDLk7MYb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNSP","BK4007"],"gpt_icon":0},{"id":"2553725524","title":"CNS Pharmaceuticals Inc. CEO John Climaco Participates in Virtual Investor \"What's Your Story\" Summer Spotlight Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2553725524","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553725524?lang=en_us&edition=fundamental","pubTime":"2025-07-22 20:45","pubTimestamp":1753188321,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CNS Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire  on July 22, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250722:nNDL4DYwJq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNSP","BK4007"],"gpt_icon":0},{"id":"2552467915","title":"CNS Pharmaceuticals Announces 1-for-12 Reverse Stock Split Effective July 22, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2552467915","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552467915?lang=en_us&edition=fundamental","pubTime":"2025-07-18 20:00","pubTimestamp":1752840026,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals Inc. announced a 1-for-12 reverse stock split, effective July 22, 2025. The company's common stock will continue trading on Nasdaq under the symbol \"CNSP\" with a new CUSIP number, 18978H508. This move consolidates every 12 existing shares into one, affecting all stockholders uniformly without altering their percentage interest in the company's equity. The par value remains at $0.001 per share, and authorized shares will be reduced to 25 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CNS Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire  on July 18, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250718:nNDL1z8d4k:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNSP","BK4007"],"gpt_icon":0},{"id":"2550658471","title":"CNS Pharmaceuticals Inc. Participates in Virtual Investor CEO Connect Segment","url":"https://stock-news.laohu8.com/highlight/detail?id=2550658471","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550658471?lang=en_us&edition=fundamental","pubTime":"2025-07-09 21:32","pubTimestamp":1752067976,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals Inc. recently participated in a Virtual Investor CEO Connect segment. During this event, CEO John Climaco provided an overview of CNSP's lead program, TPI 287, and shared key insights from his attendance at the Longwood Healthcare Leaders Spring 2025 Meeting in Cambridge, MA.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CNS Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire  on July 09, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250709:nNDL6wZlKq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNSP","BK4007"],"gpt_icon":0},{"id":"2541203190","title":"CNS Pharmaceuticals Announces Promising Results for TPI 287 in Glioblastoma Treatment at 2025 Brain Tumor Biotech Summit","url":"https://stock-news.laohu8.com/highlight/detail?id=2541203190","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541203190?lang=en_us&edition=fundamental","pubTime":"2025-06-05 20:05","pubTimestamp":1749125121,"startTime":"0","endTime":"0","summary":"CNS Pharmaceuticals Inc. has announced promising scientific research results concerning their lead program, TPI 287, at the Brain Tumor Biotech Summit. TPI 287, an abeotaxane, is in development for treating glioblastoma multiforme  and has been granted Orphan Drug Designation by the FDA for treating gliomas, pediatric neuroblastoma, and progressive supranuclear palsy. Unlike other taxanes that struggle to penetrate the blood-brain barrier , TPI 287 has shown potential in crossing the BBB to treat central nervous system tumors. In a Phase 1 trial, when used in combination with bevacizumab, TPI 287 demonstrated efficacy with 3 Complete Responses and 9 Partial Responses among 23 evaluable glioblastoma patients. These findings highlight the drug candidate's promise as a novel treatment option for brain tumors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-genera","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nNDL1JrRb0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNSP","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cnspharma.com","stockEarnings":[{"period":"1week","weight":-0.049},{"period":"1month","weight":-0.0325},{"period":"3month","weight":0.0662},{"period":"6month","weight":-0.4712},{"period":"1year","weight":-0.8935},{"period":"ytd","weight":-0.9086}],"compareEarnings":[{"period":"1week","weight":0.0034},{"period":"1month","weight":0.012},{"period":"3month","weight":0.0594},{"period":"6month","weight":0.1445},{"period":"1year","weight":0.1303},{"period":"ytd","weight":0.17}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0.166667,"avgChangeRate":-0.196826},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.081635},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.208333},{"month":4,"riseRate":0.333333,"avgChangeRate":0.014485},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.010143},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.175576},{"month":7,"riseRate":0.166667,"avgChangeRate":-0.241438},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.118916},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.104014},{"month":10,"riseRate":0.166667,"avgChangeRate":0.050333},{"month":11,"riseRate":0.5,"avgChangeRate":-0.052563},{"month":12,"riseRate":0.142857,"avgChangeRate":-0.170448}],"exchange":"NASDAQ","name":"CNS Pharmaceuticals, Inc.","nameEN":"CNS Pharmaceuticals, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CNS Pharmaceuticals, Inc.(CNSP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CNS Pharmaceuticals, Inc.(CNSP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CNS Pharmaceuticals, Inc.,CNSP,CNS Pharmaceuticals, Inc.股票,CNS Pharmaceuticals, Inc.股票老虎,CNS Pharmaceuticals, Inc.股票老虎国际,CNS Pharmaceuticals, Inc.行情,CNS Pharmaceuticals, Inc.股票行情,CNS Pharmaceuticals, Inc.股价,CNS Pharmaceuticals, Inc.股市,CNS Pharmaceuticals, Inc.股票价格,CNS Pharmaceuticals, Inc.股票交易,CNS Pharmaceuticals, Inc.股票购买,CNS Pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CNS Pharmaceuticals, Inc.(CNSP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CNS Pharmaceuticals, Inc.(CNSP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction